These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 30888254)

  • 41. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White JM
    Cochrane Database Syst Rev; 2009 Jul; (3):CD002025. PubMed ID: 19588330
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder.
    Gainer DM; Crawford TN; Fischer KB; Wright MD
    J Subst Abuse Treat; 2021 Feb; 121():108195. PubMed ID: 33357605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420
    [No Abstract]   [Full Text] [Related]  

  • 44. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
    Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
    J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medication-Based Treatment to Address Opioid Use Disorder.
    Leshner AI; Dzau VJ
    JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
    [No Abstract]   [Full Text] [Related]  

  • 47. Managing emergency department patients with opioid use disorder.
    Hazekamp CS; Sacco D
    Emerg Med Pract; 2024 Jun; 26(6):1-24. PubMed ID: 38768011
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions.
    Chang DC; Klimas J; Wood E; Fairbairn N
    Am J Drug Alcohol Abuse; 2018; 44(2):143-146. PubMed ID: 29190156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy.
    Johnson S; Martin PR
    Am J Drug Alcohol Abuse; 2018; 44(3):310-316. PubMed ID: 28829626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
    Bagley SM; Larochelle MR; Xuan Z; Wang N; Patel A; Bernson D; Silverstein M; Hadland SE; Land T; Samet JH; Walley AY
    Ann Emerg Med; 2020 Jan; 75(1):29-38. PubMed ID: 31591014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detoxification and treating opioid dependence.
    Contreras JA
    JAMA; 2006 Feb; 295(8):886-7; author reply 887-8. PubMed ID: 16493097
    [No Abstract]   [Full Text] [Related]  

  • 52. Diagnosis and Treatment of Opioid Use Disorder in 2020.
    Wakeman SE
    JAMA; 2020 May; 323(20):2082-2083. PubMed ID: 32329798
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.
    Toce MS; Chai PR; Burns MM; Boyer EW
    J Med Toxicol; 2018 Dec; 14(4):306-322. PubMed ID: 30377951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
    Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
    Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?
    Stitzer ML
    Addiction; 2013 Feb; 108(2):249-50. PubMed ID: 23331877
    [No Abstract]   [Full Text] [Related]  

  • 58. [Naltrexone and opiate substitutive treatment].
    Dupouy J; Poutrain JC; Lapeyre-Mestre M
    Therapie; 2011; 66(6):549-52. PubMed ID: 22691393
    [No Abstract]   [Full Text] [Related]  

  • 59. Medication Treatment of Adolescent Opioid Use Disorder in Primary Care.
    Carney BL; Hadland SE; Bagley SM
    Pediatr Rev; 2018 Jan; 39(1):43-45. PubMed ID: 29292291
    [No Abstract]   [Full Text] [Related]  

  • 60. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
    Kelty E; Hulse G
    Drugs; 2017 Jul; 77(11):1211-1219. PubMed ID: 28536981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.